Report Highlights

U.S. wearable heart monitors: Market Overview

The U.S. wearable heart monitoring device market was valued at USD 2.46 billion in 2024 and is forecast to reach USD 5.12 billion by 2032. Clinical ambulatory monitoring generates most revenue through single-use adhesive ECG patches, while consumer smartwatch ECG features have expanded the installed base far beyond cardiology referral. Policy shaped this two-part structure more than demand alone: Medicare payment under CPT 93241 through 93248 made extended patch monitoring financially viable for cardiology practices.

Government has been the dominant force in the clinical segment. The FDA's Center for Devices and Radiological Health sets premarket clearance standards, while CMS payment rules determine which monitoring services generate revenue. Private firms have led consumer innovation: Apple's ECG app received FDA clearance in 2018 through the 510(k) pathway, and Samsung and Withings followed with cleared features. Regulated clinical devices earn most revenue, while consumer products drive volume.

Policy-driven growth in U.S. wearable heart monitors

The first mechanism is Medicare's Physician Fee Schedule. CPT codes 93241 through 93248 cover external ECG monitoring, and CMS pays fixed rates that let cardiology groups contract with patch providers such as iRhythm Technologies. Reimbursement certainty converts into procurement volume because each covered recording becomes a billable event for the ordering physician. The Physician Fee Schedule is updated annually in the Federal Register, keeping payment rates current.

The second mechanism is remote physiologic monitoring. CMS created CPT 99453 and 99454 in 2019 for device setup and data transmission, and the CY2025 Physician Fee Schedule final rule added CPT 99445 for two-to-15-day monitoring and CPT 99470 for 10-minute management, effective January 1, 2025. The third is the FDA Breakthrough Devices Program under Section 515B of the Federal Food, Drug, and Cosmetic Act, which accelerates review of devices addressing life-threatening arrhythmias and pulls novel algorithms to market sooner.

Regulatory barriers to U.S. wearable heart monitors

Premarket clearance is the principal barrier. Most wearable ECG devices require 510(k) clearance under 21 CFR Part 807 and are classified under 21 CFR Part 870 cardiovascular regulations, administered by the FDA's Center for Devices and Radiological Health. The FY2025 standard 510(k) user fee of roughly USD 24,000 is modest, but review cycles with additional information requests typically extend commercial launch by six to twelve months.

Cybersecurity is the newest cost. Section 524B of the Federal Food, Drug, and Cosmetic Act, added by the Consolidated Appropriations Act, 2023 (Public Law 117-328), requires manufacturers of connected devices to submit vulnerability management plans and a software bill of materials. Patient data falls under HIPAA, enforced by the HHS Office for Civil Rights, and wireless components require FCC equipment authorization under 47 CFR Part 15.

Policy-created opportunities in U.S. wearable heart monitors

CMS's 2025 remote monitoring codes open a billable pathway for multi-day wearables. CPT 99445 pays for devices collecting data across two to 15 days, a window that suits short-duration patch and chest-strap products lacking a dedicated remote monitoring code. Manufacturers should design products around these code definitions, because payment follows the code rather than the device category.

The Department of Veterans Affairs offers a government-backed procurement channel through its Office of Connected Care, which runs remote monitoring programs for veterans with heart failure and atrial fibrillation. Suppliers secure VA volume through national contracts awarded via the Federal Supply Schedule. Developers of AI arrhythmia algorithms can also use FDA's Predetermined Change Control Plans guidance, finalized in December 2024, which permits pre-authorized algorithm updates without new 510(k) submissions.

Market at a Glance

Leading Market Participants

• iRhythm Technologies
• Boston Scientific
• Medtronic
• Abbott Laboratories
• Philips
• Apple
• Alphabet (Fitbit)
• Samsung Electronics
• AliveCor
• Withings

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), enforced by the FDA's Center for Devices and Radiological Health. Key compliance requirements include 510(k) or De Novo authorization, medical device reporting under 21 CFR Part 803, and cybersecurity documentation under Section 524B. The Quality Management System Regulation, which incorporates ISO 13485:2016 by reference, takes effect February 2, 2026, replacing the Quality System Regulation under 21 CFR Part 820.

HHS published a proposed update to the HIPAA Security Rule in January 2025, requiring encryption and multi-factor authentication for electronic protected health information, with finalization expected in 2026. Compared with regional peers, the U.S. framework reaches consumer launch faster than the European Union's Medical Device Regulation (Regulation (EU) 2017/745), whose transition deadlines run to 2027 and 2028. It imposes stricter premarket cybersecurity expectations than Health Canada's Medical Devices Regulations (SOR/98-282).

Long-Term Policy Outlook for U.S. Wearable Heart Monitors

By 2032, Medicare payment policy will determine whether wearable monitoring moves from episodic diagnostic use to continuous chronic management. CMS's annual Physician Fee Schedule rulemaking will continue to refine remote monitoring payment, and each cycle will decide whether multi-device care earns separate reimbursement. Manufacturers that align product claims with these codes will capture the largest share of recurring revenue.

The QMSR transition and the finalized HIPAA Security Rule will raise per-unit compliance costs, favoring established manufacturers with ISO 13485 systems and dedicated cybersecurity teams. Consumer platforms will keep pursuing FDA authorizations for additional arrhythmia and hypertension features from Apple, Samsung, and Alphabet's Fitbit, shifting revenue toward clinically validated subscription services by 2032.